Drug Trial Radar · NCT05844527
Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients
Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Nov 20, 2023
Primary completion
Sep 1, 2024
Study completion Sep 1, 2024
Sponsor
- Lead sponsor
- MedRegen LLCIndustry
- Sponsor type
- Industry
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Surgical excisions are one of the most frequent cutaneous wounds. This study will compare the safety and preliminary efficacy of a novel fixed-dose combination drug MRG-001 in pre-abdominoplasty surgical excisions and scar appearance in subjects undergoing elective abdominoplasty.
Conditions
- Wound of Skin
- Abdominal Wound
Interventions
MRG-001Drug
MRG-001 is a novel fixed-dose drug combination administered subcutaneously to mobilize stem cells and immunomodulatory cells to the wound to accelerate healing.
SalineDrug
Sterile saline will serve as placebo treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the preliminary effectiveness of MRG-001 treatment on tensile strength of the scars. The difference in Newton force will be compared between saline and MRG-001.Time frame: Week -6 to 0
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.